Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03810664 | A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations | PHASE1 | COMPLETED | 49 | — | — | Jan 18, 2019 | Apr 19, 2019 | Apr 28, 2020 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Somatrogon pre-filled PEN | EXPERIMENTAL | - |
| Somatrogon frozen liquid formulation | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Somatrogon | DRUG | A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14). |
Inclusion Criteria: * Healthy male volunteers aged 18-55 (inclusive) years * Body Mass Index (BMI) 19 to 32 kg/m2 (inclusive) and weighing at least 55 kg * Non-smoking (by declaration) for a period of at least six months prior to screening visit Exclusion Criteria: \-